Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiac neoplasms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    415 result(s) found for: Cardiac neoplasms. Displaying page 1 of 21.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-005663-17 Sponsor Protocol Number: SB3-G31-BC-E Start Date*: 2016-04-11
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
    Medical condition: Subjects with primary HER2 positive early or locally advanced breast cancer, who have completed the study treatment of SB3-G31-BC.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) FR (Completed) BG (Completed) RO (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000829-31 Sponsor Protocol Number: ML28878 Start Date*: 2013-10-10
    Sponsor Name:Roche Nederland B.V.
    Full Title: A LOCAL, OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER
    Medical condition: HER2-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001458-40 Sponsor Protocol Number: BO29159 Start Date*: 2015-05-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN® SC IN COMBINATION WITH PERJETA® AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCA...
    Medical condition: HER2−POSITIVE METASTATIC OR LOCALLY RECURRENT ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) GB (Completed) IT (Completed) ES (Completed) HU (Completed) BE (Completed) DE (Completed) FR (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002036-24 Sponsor Protocol Number: Uni-koeln-1612 Start Date*: 2014-06-24
    Sponsor Name:University of Cologne
    Full Title: A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer
    Medical condition: Patients with BRCA1- or BRCA2-associated advanced breast- and ovarian cancer which are refractory to standard therapy and for which no suitable, effective/curative therapy exists.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003509-65 Sponsor Protocol Number: HK2010 Start Date*: 2011-07-18
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO
    Full Title: Weekly therapy with Carboplatin and Docetaxel in patients with head-neck cancer with important comorbidity
    Medical condition: Patients with head and neck cancer having high comorbidity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019756-42 Sponsor Protocol Number: ECF-DCF Start Date*: 2011-03-01
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: Sequential first line chemotherapy ECF (epirubicin + cisplatin + 5-fluoruracil) followed by DCF (docetaxel + cisplatin + 5-fluoruracil) in advanced/metastatic gastric cancer HER-2 negative: a phase...
    Medical condition: patients with advanced/metastatic gastric cancer not operable HER-2 negative
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10017812 Gastric neoplasms malignant HLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017991 Gastrointestinal neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003640-24 Sponsor Protocol Number: C4221023 Start Date*: 2023-01-16
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED...
    Medical condition: metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048434 Melanoma malignant aggravated LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027155 Melanoma skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025658 Malignant melanoma of skin of eyelid, including canthus LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025661 Malignant melanoma of skin of other and unspecified parts of face LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025663 Malignant melanoma of skin of trunk, except scrotum LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025660 Malignant melanoma of skin of lower limb, including hip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025659 Malignant melanoma of skin of lip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025656 Malignant melanoma of skin of ear and external auditory canal LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025662 Malignant melanoma of skin of scalp and neck LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025664 Malignant melanoma of skin of upper limb, including shoulder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025653 Malignant melanoma of other specified sites of skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027153 Melanoma of skin, site unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025657 Malignant melanoma of skin of ear and external auricular canal LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027154 Melanoma of trunk and head LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025666 Malignant melanoma of the anus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056768 Malignant melanoma of skin of lower limb, incl hip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056767 Malignant melanoma of skin of eyelid, incl canthus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056769 Malignant melanoma of skin of upper limb, incl shoulder LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056792 Malignant melanoma of skin of trunk, excl scrotum LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077160 Central nervous system melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000364-24 Sponsor Protocol Number: ASST-2019-RADIO-ARCCS Start Date*: 2019-09-03
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Randomized open label multicentric phase II trial of Adjuvant RadioChemotherapy, Concurrent versus Sequential, in resected non-small cell lung cancer (NSCLC) patients with mediastinal involvement (...
    Medical condition: non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006109-19 Sponsor Protocol Number: STM01-102 Start Date*: 2006-09-08
    Sponsor Name:Sopherion Therapeutics, Inc.
    Full Title: A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer
    Medical condition: HER2+ Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 llt
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006454-30 Sponsor Protocol Number: 23537 Start Date*: 2023-02-09
    Sponsor Name:DIPARTIMENTO DI SCIENZE CHIRURGICHE - UNIVERSITà DEGLI STUDI DI TORINO
    Full Title: Near-infrared molecular imaging for lung cancer detection and treatment during mini-invasive surgery (Phase II Trial)
    Medical condition: To date, lung resection and lymphadenectomy remains the best curative option in patients with early-stage non-small cell lung cancer. Moreover, cancer screening programs have led to a frequent diag...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001946-32 Sponsor Protocol Number: ARRAY-162-115 Start Date*: 2021-12-07
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Multicenter, Open-label Phase Ib Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma P/071/2018
    Medical condition: Unresectable or metastatic BRAF V600-mutant melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002270-12 Sponsor Protocol Number: TRIMETA Start Date*: 2016-10-20
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Clinical trial phase II, prospective, open, randomized, controlled study to evaluate the preventive effect of trimetazidine on the cardiotoxicity of trastuzumab and chemotherapy in patients with br...
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001574-29 Sponsor Protocol Number: D967VC00001 Start Date*: 2020-10-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
    Medical condition: Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) BE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005820-17 Sponsor Protocol Number: 90111-24111 Start Date*: 2012-06-07
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Neoadjuvant BIBW 2992 followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study.
    Medical condition: Squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001705-87 Sponsor Protocol Number: BRF117019 Start Date*: 2014-03-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and ...
    Medical condition: Mutations of BRAF V600E have been identified at a high frequency in melanoma, PTC, colorectal and ovarian cancers. Such mutations have also been reported in some rare cancers such as anaplastic t...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed) NL (Completed) ES (Ongoing) NO (Completed)
    Trial results: View results
    EudraCT Number: 2019-001088-58 Sponsor Protocol Number: SELLY Start Date*: 2020-03-19
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: SEntinel Lymph node in EarLY ovarian cancer: the SELLY protocol
    Medical condition: ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004554-14 Sponsor Protocol Number: PIX111 Start Date*: 2016-11-24
    Sponsor Name:CTI BioPharma Corp.
    Full Title: A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients with Relapsed or Refractory Cancer
    Medical condition: Relapsed or refractory solid tumors (excluding those with CNS tumors) or lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-000809-12 Sponsor Protocol Number: PREDIXLumA Start Date*: 2014-11-17
    Sponsor Name:Karolinska University Hospital
    Full Title: PREDIX Luminal A - Neoadjuvant response-guided treatment of slowly proliferating hormone receptor positive tumors. Part of a set of translational phase II trials based on molecular subtypes
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006191 Breast cancer male NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007089-12 Sponsor Protocol Number: 2606 B Start Date*: 2007-02-07
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women
    Medical condition: Metastased breast cancer, first line treatment, for women with age>70 years old,Her2 positive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003752-38 Sponsor Protocol Number: om 169 Start Date*: 2003-12-09
    Sponsor Name:OSPEDALE ONCOLOGICO DI BARI
    Full Title: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer
    Medical condition: advancer breast carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:35:12 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA